Back to Search Results

Description

Details

Sub-Projects

Publications Publications

) Patents

Outcomes

Clinical Studies

News and More

(□) <u>History</u>

Similar Projects

HIV Vaccines

Project Number

1R13AI143345-01

Contact PI/Project Leader JARVIS, THALE CROSS Awardee Organization KEYSTONE SYMPOSIA

⊘ snare ▼



Abstract Text

ABSTRACT Support is requested for a Keystone Symposia conference entitled HIV Vaccines, organized by Drs. Nicole A. Doria-Rose, Thumbi Ndung'u and Gunilla Karlsson Hedestam. The conference will be held in Whistler, British Columbia from March 24-28, 2019. Despite dramatic progress in prevention and treatment of HIV, the **pandemic** continues, and two million people are newly infected each year. Thus, the need for a preventive vaccine for HIV is as urgent as ever. Intensive research in basic immunology and virology as well as empirical clinical trial data continues to yield insights that inform vaccine efforts. The 2019 HIV Vaccines conference will present the latest results from human clinical studies of candidate vaccines as well as the use of monoclonal antibodies for prevention; novel HIV neutralizing antibodies and their developmental pathways; T cell functions in killing and B cell help; structural insights and immunogen design; and the intersection of research for HIV eradication/cure with research on HIV vaccines, including interventions after very early antiretroviral therapy. We will also include a session on the process of bringing candidate vaccines to clinical trial, told from the diverse perspectives of laboratory investigators, industrial production, funders, and clinical researchers on the front lines.

Public Health Relevance Statement

PROJECT NARRATIVE Despite dramatic progress in prevention and treatment of HIV, the pandemic continues, and two million people are infected each year. Intensive research in basic immunology and virology, as well as, empirical clinical trial data continues to yield insights that inform HIV vaccine efforts. An enormous effort is pouring into the design of immunogens that can induce broadly neutralizing antibodies, and parallel efforts to understand how to induce more potent, durable antibody responses with selective adjuvants and novel methods of delivery. This conference will occur at a critical time of novel structure-based designs of immunogens to induce antiviral antibodies, as well as renewed efforts to understand how to induce effective T cell immune responses irrespective of human host genetic background.

NIH Spending Category

Biotechnology HIV/AIDS Immunization Infectious Diseases Prevention Vaccine Related

Project Terms

Academia Adjuvant Antibody Response B-Lymphocytes Animal Model Antigens Area **Biological Models British Columbia Career Choice Cell physiology Clinical Research** Clinical **Clinical Trials Educational workshop Foundations Collaborations** Data **Development Future** Human HIV-1 vaccine Genetic Government HIV **HIV** vaccine HIV-1 **Immune** Immune response **Immunology Industrialization** Industry Infection Intervention Knowledge Laboratories Methodology Methods **Monoclonal Antibodies** Measures Outcome **Pre-Clinical Model Passive Immunization Pathway interactions Prevention Preventive vaccine Research Personnel Scientist Process Production** Research **T-Lymphocyte Structure** Read More



Contact PI/ Project Leader

Title

Contact thalej@keystonesymposia.org

Other PIs

Not Applicable

Program Official

Name

GUTIERREZ, MARTIN

Contact

mgutierrez@mail.nih.gov

Organization

Name Department Type

Thank you for your feedback!

▼ Back to Search Results

Description



Sub-Projects



Publications



Patents



Clinical Studies



News and More



<u>History</u>



Similar Projects

HIV Vaccines

Contact PI/Project Leader Project Number 1R13AI143345-01 **JARVIS, THALE CROSS**

Awardee Organization KEYSTONE SYMPOSIA

Other Information

Fiscal Year

2019

FOA Administering Institutes or Centers **NATIONAL INSTITUTE OF ALLERGY** PA-18-648 **AND INFECTIOUS DISEASES** Study Section Special Emphasis Panel ZAI1 TS-D CFDA Code **DUNS Number**

079780750

Award Notice Date 14-November-2018

Project Start Date

01-January-2019

Project End Date

31-December-

2019

Budget Start 01-January-2019

Date

Budget End Date 31-December-

2019

Project Funding Information for 2019

Total Funding Direct Costs Indirect Costs \$20,400 \$20,400 \$0

Year	Funding IC	FY Total Cost by IC	
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$20,400	

855

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$20,400	Biotechnology; HIV/AIDS; Immunization; Infectious Diseases; Prevention; Vaccine Related;

品 Sub Projects

No Sub Projects information available for 1R13Al143345-01

Publications

No Publications available for 1R13Al143345-01

Patents

No Patents information available for 1R13Al143345-01

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1R13Al143345-01

Clinical Studies

No Clinical Studies information available for 1R13Al143345-01

11/25/21, 3:10 AM RePORT) RePORTER

∢ Back to Search Results

HIV Vaccines

Description

Project Number 1R13AI143345-01 **Contact PI/Project Leader JARVIS, THALE CROSS**

Awardee Organization KEYSTONE SYMPOSIA

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

<u>History</u> Similar Projects History

No Historical information available for 1R13Al143345-01

Similar Projects

No Similar Projects information available for 1R13Al143345-01